This article is more than 5 years old. Information may no longer be current.
Top 5 dermatology stories: 3D Mohs model for patient education, more
Click Here to Manage Email Alerts
“The possibility of being able to educate patients with something ‘concrete’ that they can see and touch could be a great addition to patient education,” Noelani González, MD, clinical instructor of dermatology at Mount Sinai Hospital, told Healio Dermatology regarding a recent popular story on research using a 3D-printed model before Mohs micrographic surgery.
In other top news, baricitinib significantly improved the signs and symptoms of moderate to severe atopic dermatitis compared with placebo, according to results from two phase 3 studies, BREEZE-AD1 and BREEZE-AD2, presented at the World Congress of Dermatology.
Read all of last week’s most popular stories below.
Baricitinib improves atopic dermatitis signs, symptoms at 16 weeks
The trials were identical — randomized, double-blind, placebo-controlled phase 3 monotherapy. BREEZE-AD1 included 624 adults with moderate to severe atopic dermatitis and BREEZE-AD2 included 615. Read more.
Patients maintain scalp psoriasis clearance with higher doses of mirikizumab
Clearance of scalp psoriasis was maintained at 52 weeks with higher doses of mirikizumab, a humanized monoclonal antibody, according to study data presented at the World Congress of Dermatology. Read more.
Brodalumab yields long-term skin clearance results in psoriasis
Most patients with moderate to severe plaque psoriasis who received treatment with brodalumab experienced long-term rates of skin clearance at 120 weeks, according to extension results of AMAGINE-2. Read more.
Patient education with 3D model before Mohs surgery reduces anxiety
“As dermatologists, we tend to be very visual, are always looking at ways to decrease patient anxiety before procedures, and it’s always exciting when something innovative becomes available to aid in our patients’ understanding of procedures,” González said. Read more.
Ixekizumab yields ‘durable response’ in psoriasis clearance at 5 years
Patients with moderate to severe psoriasis treated with ixekizumab showed high rates of improvement and no unexpected safety outcomes for up to 5 years of treatment, according to study results presented at World Congress of Dermatology in Milan. Read more.